ResearcherKyoto Prefectural University of MedicineActive in the last 2 years
Yusuke Yamamoto
Matched on ORCID iD 0000-0001-5604-0245; OpenAlex author ID A5111548284. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper
Papers 6
- Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intraductal papillary mucinous carcinoma. Co-author DOI 10.1186/s12885-024-12676-x↗
- Histological Differentiation Is a Pivotal Prognostic Factor Associated With the Pattern of Recurrence Following Resection of Pancreatic Adenocarcinoma. First author DOI 10.1097/mpa.0000000000001848↗
- Clinical Significance of Preoperative Albumin-Bilirubin Grade in Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-09593-9↗
- Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in the prognosis. Co-author DOI 10.1016/j.pan.2014.09.006↗
- The clinical impact of the lymph node ratio as a prognostic factor after resection of pancreatic cancer. Co-author PMID 24778048↗
- Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Co-author DOI 10.1245/s10434-011-2020-9↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Taisuke Imamura · 3 shared papers, 2021–2024 · strength 0.46
- Paper Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intradu… DOI 10.1186/s12885-024-12676-x↗
- Paper Histological Differentiation Is a Pivotal Prognostic Factor Associated With the Pattern of Recurrence Following Resecti… DOI 10.1097/mpa.0000000000001848↗
- Paper Clinical Significance of Preoperative Albumin-Bilirubin Grade in Pancreatic Cancer. DOI 10.1245/s10434-021-09593-9↗
- Teiichi Sugiura · 2 shared papers, 2021 · strength 0.27
- Ryo Ashida · 2 shared papers, 2021 · strength 0.27
- Katsuhiko Uesaka · 2 shared papers, 2021 · strength 0.27
- Katsuhisa Ohgi · 2 shared papers, 2021 · strength 0.27
- Yukiyasu Okamura · 2 shared papers, 2021 · strength 0.27
- Atsushi Shiozaki · 3 shared papers, 2014–2024 · strength 0.26
- Paper Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intradu… DOI 10.1186/s12885-024-12676-x↗
- Paper Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in … DOI 10.1016/j.pan.2014.09.006↗
- Paper The clinical impact of the lymph node ratio as a prognostic factor after resection of pancreatic cancer. PMID 24778048↗
- Eigo Otsuji · 3 shared papers, 2014–2024 · strength 0.26
- Paper Urinary microRNA-210-3p as a novel and non-invasive biomarker for the detection of pancreatic cancer, including intradu… DOI 10.1186/s12885-024-12676-x↗
- Paper Optimal duration of the early and late recurrence of pancreatic cancer after pancreatectomy based on the difference in … DOI 10.1016/j.pan.2014.09.006↗
- Paper The clinical impact of the lymph node ratio as a prognostic factor after resection of pancreatic cancer. PMID 24778048↗
- Takaaki Ito · 1 shared paper, 2021 · strength 0.13
- Ryo Morimura · 2 shared papers, 2014 · strength 0.07
- Daisuke Ichikawa · 2 shared papers, 2014 · strength 0.07
- Shojiro Hata · 1 shared paper, 2012 · strength 0.03
- Tomoo Kosuge · 1 shared paper, 2012 · strength 0.03
- Yoshihiro Sakamoto · 1 shared paper, 2012 · strength 0.03
- Kazuaki Shimada · 1 shared paper, 2012 · strength 0.03
- Satoshi Nara · 1 shared paper, 2012 · strength 0.03
- Minoru Esaki · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.